Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Posts 27 Percent Q4 Revenue Growth

NEW YORK (GenomeWeb News) – Scientific software developer Accelrys reported after the close of the market Tuesday a 27 percent increase in fourth-quarter 2011 revenues on a GAAP basis.

The San Diego-based firm reported total revenues of $39.8 million for the three-month period ended Dec. 31, compared to $31.3 million for the fourth quarter of 2010. On a non-GAAP basis, which includes fair value adjustments to deferred revenue, its revenues were down 4 percent year over year to $40.8 million from $42.5 million.

Its net income for the quarter was $14.2 million, or $.25 per share, for the fourth quarter of 2011 versus a net loss of $15.6 million, or $.28 per share, for Q4 2010. On a non-GAAP basis, its profit was $4.6 million, or $.08 per share, compared to a profit of $4.3 million, or $.08 per share, for the fourth quarter of 2010.

Accelrys' product development costs slipped to $8.8 million from $8.9 million, and its SG&A costs declined to $18.2 million from $18.4 million.

For full-year 2011, Accelrys posted revenues of $144.3 million, up 43 percent year over year from $101 million. On a non-GAAP basis, revenues were $155 million versus $124.7 million.

During the year, the firm acquired Contur Industry Holding and Contur Software and VelQuest. Those deals followed its acquisition of Symyx in 2010.

Accelrys' net income for 2011 was $1.8 million, or $.03 per share, versus a net loss of $23 million, or $.55 per share, for 2010. On a non-GAAP basis, its profit for 2011 was $19 million, or $.34 per share, up from $$10.6 million, or $.25 per share.

Its product development spending for the year increased 28 percent to $34 million from $26.5 million, and its SG&A costs climbed 11 percent to $68 million from $61.1 million.

Accelrys finished the year with $143.6 million in cash, cash equivalents, and marketable securities.

The company said it expects 2012 non-GAAP revenues to be between $164 million and $170 million with non-GAAP EPS between $.32 and $.34.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.